"Designing Growth Strategies is in our DNA"

Biobetters Market Size, Share & Industry Analysis, By Molecule Type (G-CSF Biobetters, Insulin Biobetters, Erythropoietin Biobetters, Monoclonal Antibodies Biobetters, Others), By Disease Indication (Cancer, Diabetes, Genetic disease, Neurological Disorders, Other), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)and Regional Forecast, 2024-2032

Published On : June 30, 2020 | Report ID: FBI103126 | Status : Ongoing

 

KEY MARKET INSIGHTS

Biobetters are biologically improved versiones of drugs that are already present in the market. Biobetters are different type of biosimilars that can be marketed after the innovator molecule loses it patent protection rights. CELLTRION INC. is currently developing an Antibody Drug Conjugate (ADC) biobetter that utilises Antibody- Delivery Enhancing Domain (ADED). This ADC product hat the company is developing is anticipated to help in the management of breast cancer patients. In the current market scenario, there are many bio-pharmaceutical companies that are setting to enter into biobetter development as it provides better investment opportunities. Biobetters are marketed as enhanced form of an innovator molecule hence has a better sales opportunity when compared with biosimilars.


Biobetters offer enhanced clinical efficacy and are classified as an improved form of innovator molecule. Owing to this, many biosimilars manufacturers are entering into the market of biobetters to capture customer base. Since there are not exact copies of innovator molecule, biobetters are entitled to patent protection up to 10 years. For example, Roche manufactured a biobetter of Epogen, named Mircera, to treat anemia caused by chronic kidney disease. In addition to providing higher efficacy, biobetters require lower duration for research and development when compared to its innovator products. These factors are anticipated to drive the market of biobetters over the forecast duration.

Key Market Driver -

Enhanced efficacy and high investment opportunities for the development of biobetters

Key Market Restraint -

High research and development required by biobetters compared to biosimilars


However, biobetters require twice as much more investment when compared to biosimilars. This is due to the fact that developing an enhanced version of an expired molecule is more complicated than developing an exact copy of the original molecule. This could restrain the market growth in the coming years.

Market Segmentation:


Globally, the Biobetters market can be segmented on the basis of products, operation, configuration, end-users, and region. Based on the molecule type, the market can be segmented into G-CSF biobetters, insulin biobetters, erythropoietin biobetters, monoclonal antibodies biobetters, and others. Based on the disease indication, the market can be segmented into cancer, diabetes, genetic disorders, neurological diseases, and others. Based on the distribution channel, the market can be categorised hospital pharmacy, retiail pharmacy, and online pharmacy.

Geographically, the biobetters market can be segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

Key Players Covered:


Some of the major companies that are present in the biobetters market are Novo Nordisk A/S, Eli Lily and Company, Amgen Inc., Merck & Co. Inc., Biogen Inc., F. Hoffman-LA Roche, Sanofi SA, Biogen Inc, Teva Pharmaceutical Industries Ltd., CSL Behring GmbH among other players.

Key Insights:



  • Prevalence of Major Disease by Key Countries/Region

  • Introduction of New Products/Approvals (By Major Players)

  • Key Industry Developments Mergers, Acquisitions, and Collaborations

  • Pipeline Analysis


Regional Analysis:


Geographically, the biobetters market can be categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North American region is likely to hold the largest share of the market and is anticipated to follow the same impetus over the forecast period. This is attributed to the higher prevalence of chronic disease such as cancer, diabetes, renal disease among others in the region. Combined with this, higher investment in R&D for therapeutic molecules and increased preference of key market players to seek regulatory approvals from healthcare authorities in U.S market is anticipated to drive the biobetters market in the region. Europe is projected to be the second most revenue generating market over the forecast duration. Advanced healthcare infrastructure, favorable reimbursement policies and active government funding in healthcare is projected to drive the market in the region. However, the biobetters market in countries such as China and India of the Asia-Pacific region is estimated to grow at a faster rate owing to increase in the prevalence of chronic disorders and rising geriatric population. The market in Latin America and the Middle East and Africa are expected to capture lower share in the global biobetters market.

To gain extensive insights into the market, Request for Customization


Segmentation


























ATTRIBUTE

  DETAILS

By Molecule Type



  • G-CSF Biobetters

  • Insulin Biobetters

  • Erythropoietin Biobetters

  • Monoclonal Antibodies Biobetters

  • Others



By Disease Indication



  • Cancer

  • Diabetes

  • Genetic disease

  • Neurological Disorders

  • Others



By Distribution Channel



  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy



By Geography



  • North America (USA, Canada)

  • Europe (UK, Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

  • Latin America (Brazil, Mexico, Rest of Latin America)

  • Middle East & Africa (South Africa, GCC, and Rest of the Middle East & Africa)



Biobetters Market Industry Developments



  • Green Cross Corp, one of the front runners in the competition in biobetters market is currently developing a biobetter of margetuximab in collaboration with American biotech MacroGenics.

  • In the year 2017, HANALL BIOPHARMA in partnership with Ora Inc., submitted an application for Investigational new drug to the U.S Food and Drug Administration for their product named HL036, indicated to treat dry eye disease.





  • Ongoing
  • 2023
  • 2019-2022

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients

abbvie
Styker
Galemed
Siemens Healthineers
Roche

Client Testimonials

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X